A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer

Summary

This open-label, one-center, noncomparative, two-stages phase 1B trial assessed the tyrosine kinase inhibitor donafenib tosylate tablets(400 mg/d,200mg bid) in patients with advanced, inoperable oesophageal cancer progressing after chemotherapy . The primary endpoint is the safety.The secondary endpoints are tumor response and progression-free survival.

Timeline

Start

2015-07-21

Primary completion

2020-10-29

Completion

2020-10-29

Drugs

Indications